Koh, C. Et Al. 2015. Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection a proof of concept randomised double blind placebo controlled phase 2A trial. Lancet Infectious Diseases , vol.15 , 1167-1174.

Koh, C., Canini, L., Dahari, H., Zhao, X., Uprichard, S. L., Williams, V. H., ... Winters, M. A.(2015). Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection a proof of concept randomised double blind placebo controlled phase 2A trial. Lancet Infectious Diseases , vol.15, 1167-1174.

Koh, ONUR Et Al. "Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection a proof of concept randomised double blind placebo controlled phase 2A trial," Lancet Infectious Diseases , vol.15, 1167-1174, 2015

Koh, ONUR Et Al. "Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection a proof of concept randomised double blind placebo controlled phase 2A trial." Lancet Infectious Diseases , vol.15, pp.1167-1174, 2015

Koh, C. Et Al. (2015) . "Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection a proof of concept randomised double blind placebo controlled phase 2A trial." Lancet Infectious Diseases , vol.15, pp.1167-1174.

@article{article, author={ONUR KESKİN Et Al. }, title={Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection a proof of concept randomised double blind placebo controlled phase 2A trial}, journal={Lancet Infectious Diseases}, year=2015, pages={1167-1174} }